UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000026975
Receipt number R000029209
Scientific Title Phase II trial of S-1 and lentinan combined chemotherapy for elderly patients with unresectable advanced gastric cancer
Date of disclosure of the study information 2017/04/13
Last modified on 2017/05/12 17:22:09

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Phase II trial of S-1 and lentinan combined chemotherapy for elderly patients with unresectable advanced gastric cancer

Acronym

Phase II trial of S-1 and lentinan

Scientific Title

Phase II trial of S-1 and lentinan combined chemotherapy for elderly patients with unresectable advanced gastric cancer

Scientific Title:Acronym

Phase II trial of S-1 and lentinan

Region

Japan


Condition

Condition

Unresectable advanced gastric cancer

Classification by specialty

Gastrointestinal surgery

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

To evaluate the efficacy of TS-1 plus lentinan combined chemotherapy for elderly patients with unresectable advanced gastric cancer

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase

Phase II


Assessment

Primary outcomes

Overall survival

Key secondary outcomes



Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

TS-1/lentinan

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

70 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

1.Histologically proven gastric cancer
2. Aged over 70 years at the time of registration
3.Unresectable advanced gastric cancer
4.Performance status (ECOG): 0-2
5.Previously not treated chemotherapy or radiotherapy for unresectable gastric cancer
6.Sufficient organ functions
7.Life expectance estimated>=3 months
8.Able to receive oral S-1 treatment
9.Written informed consent

Key exclusion criteria

1.Administration contraindication of S-1
2.Active infectious
3.Serious heart disease or the past history
4.Serious coexisting illness
5.Massive abdominal or pleural effusion
6.Multiple bone metastases
7.Brain metastasis or the past history
8.Active gastrointestinal bleeding
9. Mental disorder to need a psychotropic drug
10. Hypersensitivity to lentinan
11.Inappropriate patients for this study judged by the physicians

Target sample size

38


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Hideyuki Ishida

Organization

Saitama Medical Center, Saitama Medical University

Division name

Department of digestive tract and general surgery

Zip code


Address

1981 Kamoda, Kawagoe-shi, SAITAMA 350-8550, JAPAN

TEL

048-228-3619

Email

05hishi@saitama-med.ac.jp


Public contact

Name of contact person

1st name
Middle name
Last name Satomi Oyama

Organization

Saitama Medical Center, Saitama Medical University

Division name

Department of digestive tract and general surgery

Zip code


Address

1981 Kamoda, Kawagoe-shi, SAITAMA 350-8550, JAPAN

TEL

048-228-3619

Homepage URL


Email

osato@saitama-med.ac.jp


Sponsor or person

Institute

Saitama Medical Center, Saitama Medical University

Institute

Department

Personal name



Funding Source

Organization

Saitama Medical Center, Saitama Medical University

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2017 Year 04 Month 13 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2008 Year 09 Month 03 Day

Date of IRB


Anticipated trial start date

2008 Year 10 Month 30 Day

Last follow-up date


Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2017 Year 04 Month 13 Day

Last modified on

2017 Year 05 Month 12 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000029209


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name